Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia-Reference-Cited by-同舟云学术

Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia

Published:2019-12-09 Issue:19 Volume: Page:104-113
ISSN:2658-5790
Container-title:Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Besova N. S.¹^ORCID,Titova T. A.¹^ORCID,Artamonova E. V.¹^ORCID,Stroyakovskiy D. L.²,Perminova E. V.²^ORCID,Yukal’chuk D. Yu.³^ORCID,Ponomarenko D. M.³^ORCID,Belyak N. P.⁴,Orlova R. V.⁵^ORCID,Teletaeva G. M.⁶,Ratner E. Yu.⁷,Mochalova A. S.⁸,Gordeeva O. O.¹^ORCID,Zhabina A. S.⁹,Gamayunov S. V.¹⁰^ORCID,Smolin A. V.¹¹,Povyshev A. Yu.¹²^ORCID,Andrievskikh M. I.¹³^ORCID,Tryakin A. A.¹^ORCID,Stilidi I. S.¹⁴

Affiliation:

1. Federal State Budgetary Institution «N.N. Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation

2. Moscow State Budgetary Healthcare Institution «Moscow City Oncology Hospital No. 62 of the Moscow City Health Department»

3. State Budget Healthcare Institution «Regional Cancer Center»

4. Saint Petersburg State Healthcare Institution «City Clinical Oncology Center»

5. Federal State Budgetary Educational Institution of Higher Education «Saint Petersburg State University», Saint Petersburg State Healthcare Institution «City Clinical Oncology Center»

6. Federal State Budgetary Institution «Petrov National Medical Cancer Research Centre» of the Ministry of Health of the Russian Federation

7. State Autonomous Healthcare Institution «Tatarstan Regional Clinical Cancer Center» of the Ministry of Health of the Russian Federation

8. Medsi Group JSC

9. Petrov National Medical Cancer Research Centre of the Ministry of Health of the Russian Federation

10. A.F. Tsyb Medical Radiological Research Centre – Branch of Federal State Budgetary Institution «National Medical Research Radiological Center» of the Ministry of Health of the Russian Federation

11. Federal State Budget Institution «Main Military Clinical Hospital named after N.N. Burdenko»

12. Budgetary Institution of Higher Education of the KhantyMansi Autonomous District - Yugra «Khanty-Mansiysk State Medical Academy»

13. State Budgetary Healthcare Institution «Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine»

14. Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation, Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference28 articles.

1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L. Torre LA., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492.

2. Kaprin A.D., Starinskiy V.V., Petrova G.V. (eds). Cancer statistics in Russia in 2017. Moscow: Gertsen P.A. Moscow Cancer Research Institute – filial of TSYB Medical Radiological Research Center of the Ministry of Health of Russia; 2018. (In Russ.) Available at: http://www.oncology.ru/service/statistics/.

3. Kaprin A.D., Starinskiy V.V., Petrova G.V. (eds). State of Cancer Care in Russia in 2018. Moscow: Gertsen P.A. Moscow Cancer Research Institute – filial of TSYB Medical Radiological Research Center of the Ministry of Health of Russia; 2019. 236 с. (In Russ.) Available at: http://www.oncology.ru/service/statistics/.

4. Vanhoefer U., Rougier P., Wilke H., et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Co-operative Group. J Clin Oncol. 2000 Jul;18(14):2648-2657. doi: 10.1200/JCO.2000.18.14.2648.

5. Kang Y., Kang W.K., Shin D.B., et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patient with advanced gastric cancer: Efficacy and safety results. J Clin Oncol. 2016;24(18_suppl). doi: 10.1200/jco.2006.24.18_suppl.lba4018.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case of effective disease control of advanced gastric cancer following ramucirumab plus FOLFIRI in second line treatment in clinical practice;Meditsinskiy sovet = Medical Council;2020-12-21